Product_Name,Compound_Name,Indication,Phase,Mechanism of Action,NCT
Lorbrena ,lorlatinib,1st Line ALK Non-Small Cell Lung Cancer (E.U.),Registration,ALK inhibitor,
Bavencio ,avelumab,1st Line Non-Small Cell Lung Cancer (Biologic),Phase 3,Anti PD-L1,
Braftovi  and  Mektovi ,encorafinib and binimetinib,1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer,Phase 2,BRAF kinase inhibitor andMEK inhibitor,
